The influence of multiple dosing and age on the pharmacokinetics and pharmacodynamics of glipizide in patients with type II diabetes mellitus

Pharmacotherapy

Volumn 16, Issue 5 I, 1996, Pages 760-768

  Jaber, Linda A ^a   Ducharme, Murray P ^a   Edwards, David J ^a   Slaughter, Richard L ^a   Grunberger, George ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLIPIZIDE; GLUCOSE; INSULIN;

ADULT; AGED; AGING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SCREENING; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS;

ADULT; AGE FACTORS; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 0029766861     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Groop L, Groop PH, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987;10:671-8.
2. Kolterman OG. Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus. Am J Med 1985;79(suppl):23-33.
3. Balant L, Fabre J, Zahnd GR. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol 1975;8:63-9.
4. Lebovitz HE, Feinglos MN. Mechanism of action of the second-generation sulfonylurea glipizide. Am J Med 1983;75(suppl 5B):46-54.
5. Kobayashi KA, Bauer LA, Horn JR, Opheim K, Wood F, Kradjan WA. Glipizide pharmacokinetics in young and elderly volunteers. Clin Pharm 1988;7:224-8.
6. Kradjan WA, Kobayashi KA, Bauer LA, Horn JR, Opheim K, Wood FJ. Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing. J Clin Pharmacol 1989;29:1121-7.
7. Groop L, Wahlin-Boll E, Groop PH, et al. Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetes. Eur J Clin Pharmacol 1985;28:697-704.
8. Schmidt HAE, Schoog M, Schweer KH, Winkler E. Pharmacokinetics and pharmacodynamics as well as metabolism after orally and intravenously administered C14-glipizide, a new antidiabetic. Diabetologia 1973;9(suppl): 320-30.
9. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics and pharmacodynamics of glipizide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1983;21:98-107.
10. Wahlin-Boll E, Aimer L-O, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet 1982;7:363-72.
11. Jaber LA, Antal EJ, Slaughter RL, Welshman IR. Comparison of pharmacokinetics and pharmacodynamics of short and long term glyburide therapy in NIDDM. Diabetes Care 1994;17: 1300-6.
12. Wahlin-Boll E, Melander A, Sartor G. High-performance liquid chromatographic determination of glipizide and some other sulphonylurea drugs in serum. J Chromatogr 1979;164: 541-6.
13. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
14. D'Argenio DZ, Schumitzky A. ADAPT-II user's guide. Los Angeles: Biomedical Simulations Resource, University of Southern California, 1992.
15. Groop L, Harno K. Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics. Acta Endocrinol 1980;239:44-52.
16. Stenman S, Melander A, Groop PH, Groop LC. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993;118:169-72.
17. Melander A, Lebovitz HE, Faber OK. Sulfonylureas: why, which, and how? Diabetes Care 1990;13(suppl 3):18-25.
18. Polonsky KS. The β-cell in diabetes: from molecular genetics to clinical research. Diabetes 1995;44:705-17.
19. Melander A, Bitzen P-O, Faber O, Groop L. Sulphonylurea anti-diabetic drugs: an update of their clinical pharmacology and rational therapeutic use. Drugs 1989;37:58-72.
20. Karam JH, Sanz E, Salomon E, Nolte MS. Selective unresponsiveness of pancreas β-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes 1986;35:1314-20.
21. Grunberger G. Maintenance of sulfonylurea responsiveness in NlDDM: randomized double-blind study of intermittent glyburide therapy. Diabetes Care 1992;15:696-9.